CompBrief BY VELARION

Companies PROKIDNEY CORP.

PROKIDNEY (PROK): executive pay, fiscal 2025

Free brief. Every figure links to the company’s own filing.

Email me PROKIDNEY CORP.’s executive pay brief as a PDF

It arrives in about 2 minutes, with every figure cited to its filing.

After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.

CEO total pay$2,956,447CEO Bruce Culleton · source

CEO pay, last three years

  • $8,712,140FY2023
  • $1,015,802FY2024
  • $2,956,447FY2025

CEO total pay was $2,956,447 in fiscal 2025, up from $1,015,802 in fiscal 2024.

FY2025: salary $687,738 · bonus $0 · stock awards $0 · option awards $1,775,166

Order PROK

Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

Executives and directors

Full detail

Every table from the filing. Open any section.

Summary compensation table
Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Bruce Culleton$687,738$0$0$1,775,166$478,080$0$15,463$2,956,447
Chief Executive Officer
Todd Girolamo466,15300642,460243,000015,9491,367,562
Chief Legal Officer
James Coulston465,92300642,460243,000015,9491,367,332
Chief Financial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Bruce Culleton$2,956,447$1,015,802$8,712,140↑ +1,940,645
Todd Girolamo1,367,5621,260,8992,295,042↑ +106,663
James Coulston1,367,332950,1272,286,608↑ +417,205

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Incentive-plan design — the Compensation Discussion & Analysis

The Talent and Compensation Committee seeks to provide compensation that is competitive in light of current market conditions and industry practices, using market data from peer companies and compensation surveys to guide levels and program targets. The Committee also considers factors such as the criticality of each executive officer’s role, depth and breadth of experience, internal equity, performance, retention concerns, and relevant compensation trends.

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultantFW Cook
Clawback policytrue
Anti-hedging—
Anti-pledging—
Equity grants and outstanding awards

No plan-based awards are on file for this fiscal year.

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Todd GirolamoOption29,3431.61—
James CoulstonOption67,74410.33—
Todd GirolamoOption78,5428.43—
James CoulstonOption78,5428.43—
Todd GirolamoRSU81,929—183,521
James CoulstonRSU88,287—197,763
Todd GirolamoOption145,16610.33—
James CoulstonOption154,6881.61—
Todd GirolamoOption168,7501.61—
Bruce CulletonOption202,08413.08—
Bruce CulletonOption500,0001.69—
Todd GirolamoOption528,1251.23—
James CoulstonOption528,1251.23—
Bruce CulletonOption1,000,0001.69—
Bruce CulletonOption1,459,2501.23—
Director compensation
DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Pablo LegorretaNot independent · Board Chair · Research & Development$72,250—$72,383——$144,633
Alan M. Lotvin, M.DIndependent · Audit · Compensation (Chair)71,000—72,383——143,383
Brian J.G. Pereira, M.DIndependent · Nominating and Corporate Governance · Audit · Research & Development (Chair)67,000—72,383——139,383
Jennifer FoxIndependent · Audit (Chair)60,000—72,383——132,383
William F. DoyleIndependent · Lead Independent Director · Nominating and Corporate Governance (Chair) · Compensation57,500—72,383——129,883
Uma Sinha, Ph.DIndependent · Compensation · Research & Development52,500—72,383——124,883
José Ignacio Jiménez SantosIndependent · Nominating and Corporate Governance45,000—72,383——117,383
Bruce Culleton, M.DEmployee director · Research & Development—————0

Board fee structure and ownership guideline

Annual cash retainer$42,500
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)20,000 / 15,000 / 10,000
Stock ownership guideline—

Total cost of the board

ComponentFY2025
Cash retainers and fees$425,250
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$425,250

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

Peer group, and who names PROKIDNEY as a peer

Companies that benchmark against PROK

No companies currently name PROK as a compensation peer in their most recent disclosure.

This is the complete answer, not a partial one — the list is never padded.

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1PROKIDNEY CORP.2025Bruce Culleton$687,738$0$1,775,166$478,080$2,956,447

Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Say-on-pay history and pay ratio
Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-05-28—————

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.

Say-on-pay — history, company’s computation

Meeting yearMeeting dateApproval — company’s computation
20262026-05-28—a

a. Voting standard not stated in the filing.

Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

Insider trades since the proxy

No insider equity transactions reported since the proxy statement.

Sources (15 citations)

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

  • Section 01, Bruce Culleton. DEF 14A, filed 2026-04-17. Section “Executive Compensation”. As printed: 2,956,447. View filing ↗
  • Section 01, Todd Girolamo. DEF 14A, filed 2026-04-17. Section “Executive Compensation”. As printed: 1,367,562. View filing ↗
  • Section 01, James Coulston. DEF 14A, filed 2026-04-17. Section “Executive Compensation”. As printed: 1,367,332. View filing ↗
  • Section 08, Pablo Legorreta. DEF 14A, filed 2026-04-17. Section “Director Compensation”. As printed: 144,633. View filing ↗
  • Section 08, Alan M. Lotvin, M.D. DEF 14A, filed 2026-04-17. Section “Director Compensation”. As printed: 143,383. View filing ↗
  • Section 08, Brian J.G. Pereira, M.D. DEF 14A, filed 2026-04-17. Section “Director Compensation”. As printed: 139,383. View filing ↗
  • Section 08, Jennifer Fox. DEF 14A, filed 2026-04-17. Section “Director Compensation”. As printed: 132,383. View filing ↗
  • Section 08, William F. Doyle. DEF 14A, filed 2026-04-17. Section “Director Compensation”. As printed: 129,883. View filing ↗
  • Section 08, Uma Sinha, Ph.D. DEF 14A, filed 2026-04-17. Section “Director Compensation”. As printed: 124,883. View filing ↗
  • Section 08, José Ignacio Jiménez Santos. DEF 14A, filed 2026-04-17. Section “Director Compensation”. As printed: 117,383. View filing ↗
  • Section 08, Bruce Culleton, M.D. DEF 14A, filed 2026-04-17. Section “Director Compensation”. As printed: 0. View filing ↗
  • Section 06, 2026 vote. Form 8-K, filed 2026-04-17. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
  • Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
  • Section 09b board cost (computed). Computed. Cash 425,250 + equity 0 + all other 0 = 425,250, summed across the director compensation table rows.
  • PROKIDNEY CORP. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in PROKIDNEY CORP.'s own proxy. As printed: 2,956,447. View filing ↗
Get the full report — $1,500